Abstract

http://ssrn.com/abstract=1425564
 
 

Footnotes (171)



 


 



When and How to Defer to the FDA: Learning from Michigan's Regulatory Compliance Defense


Jason C. Miller


affiliation not provided to SSRN

May 10, 2009

Michigan Telecommunications and Technology Law Review, Vol. 15, p. 565, 2009

Abstract:     
Should FDA approval of a drug affect products liability litigation? This remains one of the most debated questions in the law. Although the Supreme Court recently held that state tort law is not forced to defer to the FDA's finding that a drug is safe through preemption, states remain free to defer to the FDA by providing a regulatory compliance defense in state substantive law. Michigan made exactly such a choice in enacting the only complete defense for FDA-approved drugs. Compliance with FDA regulations conclusively establishes a lack of products liability under Michigan law. With preemption seemingly off the table after Wyeth v. Levine, advocates of greater deference to the FDA may use Michigan as a model for legislation in other states. Much can be learned from examining Michigan's law.

Michigan's regulatory compliance defense properly recognizes that an FDA-approved drug carrying an FDA-approved label should not be considered defective. However, the statute's absolute immunity provides no compensation for injured parties in any circumstance, including situations where the FDA process has failed to protect consumers. This Note examines the question of FDA approval in state tort actions, discusses Michigan's answer to that question, and offers a proposal that would block most private actions against FDA-approved drugs (as Michigan has done), but would allow a state attorney general to bring suits in certain circumstances. The state attorney general model detailed in this Note stakes out a middle ground in the debate over the significance of FDA approval. The proposal recognizes the primacy of the FDA, but also recognizes the need for a back-up that can provide deterrence and compensation in the few cases that slip through the FDA's regulatory cracks.

Number of Pages in PDF File: 25

Keywords: FDA approval, tort law, products liability, regulatory compliance defense, preemption

Accepted Paper Series





Download This Paper

Date posted: June 26, 2009 ; Last revised: July 20, 2009

Suggested Citation

Miller, Jason C., When and How to Defer to the FDA: Learning from Michigan's Regulatory Compliance Defense (May 10, 2009). Michigan Telecommunications and Technology Law Review, Vol. 15, p. 565, 2009. Available at SSRN: http://ssrn.com/abstract=1425564

Contact Information

Jason C. Miller (Contact Author)
affiliation not provided to SSRN ( email )
No Address Available
Feedback to SSRN


Paper statistics
Abstract Views: 947
Downloads: 98
Download Rank: 161,747
Footnotes:  171

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo4 in 0.328 seconds